| abstract |
The invention relates to a pharmaceutical composition intended for oral administration for the treatment of cancer in a patient, comprising a therapeutically effective amount of (3,5-bis-trifluoromethyl) -N- [4-methyl-3- (4-pyridin-3-ylpyrimidin-2- Ilamino) phenyl] benzamide (NRC-AN-019) or its pharmaceutically acceptable salt; lipophilic phase and fillers. It also describes the use of this composition and the method of treating cancer with it. |